Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.84 - $24.94 $1,884 - $2,494
100 New
100 $2,000
Q4 2023

Feb 14, 2024

SELL
$12.19 - $22.43 $39,008 - $71,776
-3,200 Reduced 47.76%
3,500 $75,000
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $74,368 - $113,680
5,600 Added 509.09%
6,700 $113,000
Q2 2023

Aug 14, 2023

BUY
$11.66 - $26.0 $10,494 - $23,400
900 Added 450.0%
1,100 $15,000
Q1 2023

May 15, 2023

SELL
$19.47 - $28.49 $114,873 - $168,091
-5,900 Reduced 96.72%
200 $4,000
Q4 2022

Feb 14, 2023

BUY
$18.08 - $30.0 $110,287 - $183,000
6,100 New
6,100 $143,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $862M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.